Active — Not RecruitingNot Applicable

Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension

France550 participantsStarted 2024-03-01

Plain-language summary

The ACTIOBIO study aims to evaluate the prognostic value of Activin-A and FSTL3 in a large cohort of patients with precapillary pulmonary hypertension, including pulmonary arterial hypertension (Group 1), pulmonary hypertension associated with lung diseases (Group 3), and chronic thromboembolic pulmonary hypertension (Group 4).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

1. Male or female ≥ 18 years of age 2. Precapillary PH documented by right heart catheterization: * mean pulmonary arterial pressure (mPAP) \> 20 mmHg, * pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg; * pulmonary vascular resistance (PVR) \> 2 WU 3. Pulmonary arterial hypertension (group 1) or PH associated with lung disease (group 3) or chronic thromboembolic PH (group 4) 4. Patient registered in the French PH registry 5. Patient capable of understanding the study procedures 6. Affiliation to a social security regime (or exemption)

What they're measuring

Lung-transplant-free survival at 2 years

Timeframe: Two years

Trial details

NCT IDNCT07253363

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04

View on ClinicalTrials.gov More Pulmonary Hypertension trials